On Jul. 20, 2020, scientists at HDT Bio, PAI Life Sciences, and the University of Washington announced they had developed a COVID-19 vaccine candidate that rapidly generates a broad immune response against coronavirus with just one injection.

The vaccine candidate, HDT-301 is a stable RNA vaccine formulated using HDT Bioﾒs proprietary hybrid lipid inorganic nanoparticle (LIONﾙ) formulation platform.